Skip to search formSkip to main contentSkip to account menu

vaniprevir

National Institutes of Health

Related topics

Related topics

1 relation
MK-7009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
ForceGen 3D structure and conformer generation: from small lead-like molecules to macrocyclic drugs
We introduce the ForceGen method for 3D structure generation and conformer elaboration of drug-like small molecules. ForceGen is… 
2017
2017
Phase Separation Macrocyclization in a Complex Pharmaceutical Setting: Application toward the Synthesis of Vaniprevir.
A phase separation/continuous flow strategy employing an oxidative Glaser-Hay coupling of alkynes has been applied toward the… 
2016
2016
Vaniprevir plus peginterferon alfa‐2b and ribavirin in treatment‐experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies
Vaniprevir is a macrocyclic hepatitis C virus (HCV) non‐structural (NS)3/4A protease inhibitor. The objective of these phase 3… 
2015
2015
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
AbstractBackgroundVaniprevir is a potent macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. This… 
2015
2015
Liver-to-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-Infected Patients
Background Some drugs that are actively taken up into the liver exhibit greater than dose proportional increases in plasma… 
2014
2014
Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study
BackgroundVaniprevir (MK-7009) is a hepatitis C virus (HCV) non-structural 3/4a protease inhibitor which significantly increases… 
Review
2014
Review
2014
Virus-related liver cirrhosis: molecular basis and therapeutic options.
Chronic infections with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) are the major causes of cirrhosis globally. It… 
2014
2014
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
2013
2013
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
Review
2011
Review
2011
Emerging therapeutic options in hepatitis C virus infection.
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is pegylated interferon alfa in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)